Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Short-term Investments (2022 - 2025)

Historic Short-term Investments for Summit Therapeutics (SMMT) over the last 4 years, with Q3 2025 value amounting to $321000.0.

  • Summit Therapeutics' Short-term Investments fell 61.92% to $321000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $321000.0, marking a year-over-year decrease of 61.92%. This contributed to the annual value of $307.5 million for FY2024, which is 16780.62% up from last year.
  • As of Q3 2025, Summit Therapeutics' Short-term Investments stood at $321000.0, which was down 61.92% from $319000.0 recorded in Q2 2025.
  • Summit Therapeutics' 5-year Short-term Investments high stood at $307.5 million for Q4 2024, and its period low was $317000.0 during Q1 2024.
  • For the 4-year period, Summit Therapeutics' Short-term Investments averaged around $116.1 million, with its median value being $132.3 million (2023).
  • Its Short-term Investments has fluctuated over the past 5 years, first tumbled by 9981.56% in 2024, then skyrocketed by 4715205.05% in 2025.
  • Over the past 4 years, Summit Therapeutics' Short-term Investments (Quarter) stood at $300.0 million in 2022, then plummeted by 61.73% to $114.8 million in 2023, then soared by 167.81% to $307.5 million in 2024, then tumbled by 99.9% to $321000.0 in 2025.
  • Its Short-term Investments was $321000.0 in Q3 2025, compared to $319000.0 in Q2 2025 and $149.8 million in Q1 2025.